News
Programme news and announcements
Announcements are made first through a Regulatory Information Service (RNS), which prevails over this website. Every regulatory announcement is listed under RNS announcements.
13 October 2026 | SVN-001
Solvonis and Portugal’s National Addiction Institute sign an MoU to advance planned European expansion of SVN-001 Phase 3 trial
Agreement with ICAD and clinical partner Panegreen to assess adding Portuguese sites to the alcohol addiction trial.
Read the announcement2026
13 Oct 2026SVN-001Solvonis and Portugal’s National Addiction Institute sign an MoU to advance planned European expansion of SVN-001 Phase 3 trial
29 Sep 2026SVN-001SVN-001 Ahead of Established and Emerging AUD Treatments
3 Sep 2026SVN-114Vital Patent milestone achieved – SVN 114
25 Aug 2026CorporateSolvonis Raises £1.3 Million
6 Aug 2026SVN-015SVN-015 Advances in NIDA-Funded Studies Following Encouraging Initial Screening
13 Jul 2026CorporateWater Tower Research Initiates Coverage
22 Jun 2026SVN-002Solvonis Announces Positive SVN-002 Bridging Data
19 Jun 2026CorporateSolvonis Announces Result of Annual General Meeting
5 May 2026CorporateCSO Speaks at US National Research Meeting
29 Apr 2026ResultsFinancial year 2025 results & SVN-001 strategy refinement
22 Apr 2026CorporateSolvonis Appoints Water Tower Research
20 Apr 2026CorporateTrump’s EO positive signal for rapid-acting CNS therapies in the US
8 Apr 2026PTSDSecond U.S. Patent from PTSD Programme
31 Mar 2026PTSDSolvonis Granted U.S. Patent from PTSD Discovery Programme
10 Mar 2026SVN-114SVN-114 selected as the lead candidate for PTSD discovery programme
28 Jan 2026SVN-015Expansion of SVN-015 into depression following positive preclinical data
7 Jan 2026PTSDU.S. Patent allowance received for PTSD discovery programme
2025
22 Dec 2025PipelineResearch and Development Update – Q4 2025
3 Dec 2025SVN-015SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction
27 Oct 2025BoardSolvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth
16 Oct 2025CorporateRaises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders
12 Aug 2025PTSDSVN-SDN-14 PTSD - Positive pre-clinical results
11 Jul 2025Corporate£1.0 million subscription by major shareholders to accelerate AI drug discovery programme
26 Jun 2025CorporateInitiation of research coverage by Singer Capital Markets
23 Jun 2025DiscoveryAllowance of U.S. patent covering AI-supported CNS discovery programme compounds
11 Jun 2025DiscoveryInitiation of artificial intelligence-supported CNS drug discovery programme
28 May 2025CorporateCompletion of the acquisition of Awakn Life Sciences Corp
11 Mar 2025BoardStatement on the appointment Dr Renata Crome, Non-Executive Director.